Conference on Recombinant
Antibodies
Examining the latest developments in the
field of antibody engineering
To be held at 22nd - 23rd
January 2009, BSG Conference Centre, London, UK
Download Brochure
("If
you cannot view the brochure, kindly right click on the link and
click "save target as")
|
Background
Information
Key Speakers
Dr Matthew Baker, Chief Scientific Officer,
Antitope
Dr David Blakey, Chief Scientist, Oncology, AstraZeneca /
MedImmune
Dr Michael Kragh, Director of Antibody Pharmacology, Symphogen
Dr. Christian Klein, Department Head Discovery Oncology, Pharma
Research, Roche Diagnostics
Dr Rathin C. Das, President, Affitech USA, Senior VP Corp
Development & CBO, Affi tech Group
Dr Frederic Fellouse, Samuel Lunenfeld Research Institute, Mount
Sinai Hospital
Dr Leon Hooftman, Chief Medical Officer, Chroma Therapeutics
Dr René Hoet, Sr. Director, Research, Genmab
Dr Candi Soames, Partner, Edwards Angell Palmer & Dodge
Dr David R. Buckler, Director of Research Alliances, Dyax
Philippe Stas, CEO, Algonomics, President, European
Immunogenicity Platform
Dr Michael Steward, Manager, Biopharm CEDD Domantis
Professor Serge Muyldermans, VIB Department of Molecular and
Cellular Interactions, Vrije Universiteit Brussel
Dr Ulrich Rothbauer, BioCenter, Department of Biology, Ludwig
Maximilians University
Dr Philip Webber, European Patent Attorney, Frank B Dehn
Dr Hilde Revets, Director Cell Biology and Immunology, Ablynx
Dear Colleague,
The protein
therapeutics market remains one of the fastest growing segments
of the pharma market, and recombinant antibodies have gained
enormous importance for clinical applications. Visiongain’s
greatly anticipated event will enable you to examine these
current applications, and latest developments in the fi eld of
antibody engineering. Recombinant antibodies have distinct
advantages compared with conventional antibodies such as, rapid
growth and ease of manipulation, making them the ideal choice
for expression of non-glycosylated peptides and proteins.
Innovative product classes such as alternative binding molecules
will further expand their use, whilst novel engineered
production hosts and integrated technology platforms hold huge
potential for future applications. By attending Visiongain’s 2nd
Annual Recombinant Antibodies Conference you will gain a
comprehensive outlook for the protein therapeutics market from
product development to strategic issues and market trends.
Reasons to
register today:
-
Hear from key
researchers and decision makers in the field of antibody
engineering
-
Examine the
current market environment for therapeutic antibodies and
assess market potential
-
Discover
recent developments in antibody display and selection
techniques
-
Understand
the regulatory requirements for recombinant therapeutic
antibodies and hear strategies for protecting antibodies
-
Learn
practical measures for predicting and minimising
immunogenicity
-
Identify
potential protein therapeutics areas for partnerships and
collaboration
-
Be part of a
unique networking opportunity
I look forward
to meeting you at the conference.
Best regards
Andrea Charles
Head of Conferences
Who should attend:
VPs, Directors,
Heads and Managers of:
-
Research &
Development
-
Protein
Engineering
-
Antibody
Engineering
-
Preclinical
Development
-
Clinical
Development
-
Antibody
Development
-
Immunology
(Research)
-
Immunogenicity
-
(Clinical)
Oncology
-
Oncology
Research
-
Oncology
Discovery
-
IP/ Patents
-
New Product
Development
-
Business
Development
-
Marketing
-
Licensing
TOP |
|
Day 1 Thursday 22nd
January 2009
09:00 Registration
and refreshments
09:30 Opening address from the
chair
Dr Rathin C. Das
President, Affitech USA
Senior VP Corp Development & CBO, Affitech Group
09.40 Therapeutic antibodies:
Market trend and evolving discovery and development outlook
-
Current market and business
trend
-
Increasing the functional
efficacy of therapeutic antibodies
-
Cell Based Antibody Selection (CBAS™):
a proprietary system of Affitech for discovery and development
of therapeutic antibodies
Dr Rathin C. Das
President, Affitech USA
Senior VP Corp Development & CBO, Affitech Group
10.20 Strategies for improved
antibody analysis
Dr René Hoet
Sr. Director, Research
Genmab
11:00 Morning refreshments
11:20 Recent developments in
antibody selection techniques
Professor Serge Muyldermans
VIB Department of Molecular and Cellular Interactions
Vrije Universiteit Brussel
12:00 Mining for magic
bullets: High throughput screening of phage display antibody
libraries
-
Phage antibody libraries with
key design features are a rich source of high affinity human
antibodies against a broad range of targets with therapeutic
relevance
-
Effective mining of these
libraries to obtain binders amenable to rapid development
toward clinical testing relies on automated and high
throughput screening
-
Key challenges in generating
and managing data from high throughput phage antibody library
screening will be discussed, and approaches used at Dyax to
address these challenges will be presented
-
Specific case study examples
will highlight rapid advancement of leads from screening to
preclinical development without the need for affinity
maturation
Dr David R. Buckler
Director of Research Alliances
Dyax
12.40 Networking Lunch
14.00 Synthetic therapeutic
antibodies
-
Highly functional minimalist
synthetic antibody libraries
-
Beyond the Natural Immune
System:
-
Conformation-specific
antibodies
-
Antibodies against structured
RNA
-
Detecting post-translational
modifications
-
Targeting integral membrane
proteins
Dr Frederic Fellouse
Samuel Lunenfeld Research Institute
Mount Sinai Hospital
14:40 Presentation to be announced
Dr Hilde Revets
Director Cell Biology and Immunology
Ablynx
15:20 Afternoon refreshments
15:40 Chromobodies to target
and trace antigens in living cells
-
Cell based selection of
functional chromobodies
-
Chromobodies for real time
detection of protein interactions
-
Tracing of dynamic processes in
living cells
Dr. Ulrich Rothbauer
BioCenter, Department of Biology
Ludwig Maximilians University
16:20 Therapeutic effects of antibody
mixtures
Dr. Michael Kragh
Director of Antibody Pharmacology
Symphogen
17:00 Closing remarks from the chair
7:15 Networking drinks
Take your discussions further and
build new relationships in a relaxed and informal setting.
TOP |
|
Day 2
Friday 23rd January 2009
09:00 Registration and
refreshments
09:30 Opening address from
chair
09:40 Strategies for obtaining
and protecting your patents
-
Details of how antibodies can
be patented
-
EPO and USPTOs’ views on
patenting CDRs
-
Maximising your antibody patent
portfolio
-
Options for dealing with
competitors’ patents
Dr Philip Webber
European Patent Attorney
Frank B Dehn
10:20 Patent protection via epitope mapping
-
Protein claiming strategies: US
PTO and EPO requirements
-
Distinguishing known antibodies
and novel antibodies
-
Impact of current IP on the
future of binding ligands (dabs, scaffolds,
framework and CDR shuffling)
Dr Candi Soames
Partner
Edwards Angell Palmer & Dodge
11:00 Morning refreshments
11:20 Immunogenicity risk
assessment and regulatory guidelines in therapeutic antibodies
-
Overview of the immunogenicity
causes and drivers
-
Applying the novel EMEA
guidance and industry whitepapers to antibody therapeutics
-
Clinical and non-clinical
strategies to assess immunogenicity of therapeutic antibodies
-
Selected case studies
Philippe Stas
CEO, Algonomics
President, European Immunogenicity Platform
12:00 New recommendations for
first in human studies for
antibodies
-
Lessons to be learned after the
phase I TGN 1412 study in healthy volunteers
-
NOAEL or MABEL for calculation
of first dose in phase I studies
-
Definition of ‘high risk
molecules’
-
EU CTD and phase I
Dr Leon Hooftman
Chief Medical Officer
Chroma Therapeutics
12.40 Networking Lunch
14.00 Overcoming adverse
immunogenicity against therapeutic antibodies
-
Why immunogenicity of
biological medicines is such a big problem, and understanding
the consequences
-
Strategies and tools for
assessing immunogenicity
-
An expert perspective on the
main pitfalls and failures in the assessment of immunogenicity:
how to avoid them
Dr Matthew Baker
Chief Scientific Officer
Antitope
14:40 The development of
therapeutic antibodies for oncology
Dr David Blakey
Chief Scientist, Oncology
AstraZeneca/MedImmune
15:20 Afternoon refreshments
15:40 GA101, a next generation
type II CD20 antibody for the therapy of B cell malignancies
Dr. Christian Klein
Department Head Discovery
Oncology, Pharma Research
Roche Diagnostics
16:20 Domain antibodies as an
alternative to traditional antibodies
Dr Michael Steward
Manager, Biopharm CEDD
Domantis
17:00 Chair’s closing remarks
17:10 End of conference
TOP
|
To download conference brochure, please
click here.. |
|
|
For more
information, kindly contact us
at :
 Bharat Book
Bureau
207, Hermes Atrium, Sector 11, PO
Box.54, CBD Belapur, Navi Mumbai - 400 614, India.
Phone : +91 22 2757 8668 / 2757 9438
Fax : +91 22 2757 9131
E-mail :
info@bharatbook.com
Website :
www.bharatbook.com
|
